BNET Industries
Wyeth (WYE) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $22.3B
- Profit
- Dec 31 2007
- $4.6B
- Market Cap
- Jul 23 2008
- $60.7B
Latest News and Analysis
Wyeth Q2 2008 Earnings Call Transcript
Wyeth Pharmaceuticals WYE Q2 FY08 Earnings Call
Top Drug Companies' Earnings Beat Forecasts
By Ben Hirschler LONDON (Reuters UK) - The world's two biggest drugmakers, Pfizer PFE and GlaxoSmithKline GSK, both beat expectations for quarterly earnings on Wednesday, as did Wyeth WYE, indicating the sector's resilience. Although all three companies face major threats from generic competition, the latest...
Top Drug Companies' Earnings Beat Forecasts
By Ben Hirschler LONDON (Reuters) - The world's two biggest drugmakers, Pfizer Inc PFE and GlaxoSmithKline Plc GSK, both beat expectations for quarterly earnings on Wednesday, as did Wyeth WYE, indicating the sector's resilience. Although all three companies face major threats from ...
Wyeth Profit Falls 7 Percent, But Beats Estimates
NEW YORK (Reuters) - Wyeth WYE on Wednesday said second-quarter earnings fell 7 percent, hurt by generic forms of its Protonix ulcer drug, although results beat estimates as they were helped by its vaccine for childhood infections and a drug for...
Just What the Doctor Ordered: Comparing the Pharma ETFs
Mike Havrilla submits: click to enlarge The top four holdings in the Pharma HOLDRs PPH account for over 60% of the 21 components and include Johnson & Johnson (JNJ – 25.8%), Pfizer (PFE – 15.6%), Abbott Labs (ABT – 11.8%), and Merck (MRK – 10%). However, this is by...
Wall St. Futures Rise; Eyes on Earnings, Beige Book
(Reuters) Both Dow Jones futures and S&P 500 futures were up 0.55 percent at 0945 GMT (5:45 a.m. EDT), while Nasdaq futures were 71 percent higher. Earnings were due from more than 40 S&P 500 companies, including Anheuser-Busch BUD,...
Earnings Preview: Wyeth
Wyeth WYE is expected to report Q2 earnings before market open Wednesday, July 23, with a conference call scheduled for 8:00 am ET. Guidance Analysts are looking for a profit of 87c on revenue of $5.69B. The consensus range is 83c to 91c for EPS, and revenue of $5.49B to...
Is Elan in Double Trouble?
Mike Huckman submits: A few weeks ago I blogged about a couple of analysts cautioning investors that shares of Irish drugmaker Elan ELN would be volatile surrounding the Alzheimer's conference the end of this month. That has certainly proven to be the case, especially on Friday as the second...
Cowen's "Elan" for Elan Corp.
Mike Huckman submits: At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call...
Pfizer Makes a Deal, Wyeth and Elan Release Alzheimer's Drug Results
Mike Huckman submits: Last week, Pfizer PFE made a major announcement regarding the world's top-selling statin, Lipitor. Pfizer struck a deal with the Indian generic drugmaker Ranbaxy to ward off the threat of generic competition for Lipitor until late 2011. I know there were a lot of market pressures...
In Tech We Trust - Fast Money Recap (6/20/08)
Recap of Fast Money, Friday June 20. Dow Falls Below 12,000 by SA Editor Joan Wickham
Elan, Wyeth: Response to Skeptics on Alzheimer's Data
Ketan Desai submits: Elan ELN and Wyeth WYE presented their phase II data on June 17th with bapineuzumab in Alzheimer’s Disease. In brief, the data showed that out of the 240 patients in the trial, those who had no apoE4 had statistical improvement compared to those who did. The skeptics...
Alzheimer Drug Fails Trial
Eben Tessari submits: Image via Wikipedia by Eben Tessari
Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine
Derek Lowe submits: The long-running saga of Elan's ELN attempt to come up with a vaccine for Alzheimer's disease continues. There have been bold attempts, setbacks, rethinks, more setbacks, and now they're starting up again. Dosing of the latest version of their vaccine against the beta-amyloid protein, known as...
Hedge Fund Tracking: Blue Ridge Capital (John A. Griffin)
Market Folly submits: (Note: Before reading this update, make sure you check out the preface to the series I'm doing on Hedge Fund 13Fs here.) Alright, so now we're cruising through these hedge funds having already covered Steven Mandel's Lone Pine Capital and Boone Pickens' BP Capital. Next up,...
Wyeth and Elan Face Big Test on Alzheimer's Drug
Mike Huckman submits: Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July. We just finished back-to-back coverage of the world's largest oncology and diabetes conferences. Now...
Wyeth Q1 2008 Earnings Call Transcript
Wyeth Q1 2008 Earnings Call Transcript
Wyeth Q4 2007 Earnings Call Transcript
Wyeth Q4 2007 Earnings Call Transcript
Wyeth Q3 2007 Earnings Call Transcript
Wyeth Q3 2007 Earnings Call Transcript
Wyeth Q2 2007 Earnings Call Transcript
Wyeth Q2 2007 Earnings Call Transcript
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1926
- CEO: Mr. Bernard J. Poussot
Wyeth is engaged in the discovery, development, manufacture, distribution and sale of a line of products in three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare) and Fort Dodge Animal Health (Animal Health). Co.'s Pharmaceutical products include branded human ethical pharmaceuticals, biotechnology products, vaccines and nutrition products, while its Consumer Healthcare products include analgesics, cough/cold/allergy remedies, nutritional supplements, and hemorrhoidal, asthma and personal care items sold over-the-counter, and its Animal Health products include vaccines, pharmaceuticals, parasite control and growth implants.
Key Competitors
Wyeth Company Info
Board of Directors
Mr. Robert Essner
Chairman
Mr. Bernard J. Poussot
Mr. Gary L. Rogers
Mr. Michael J. Critelli
Mr. John R. Torell III
Mr. Robert M. Amen
Mr. John D. Feerick
Dr. Frances D. Fergusson Ph.D.
Mr. Victor F. Ganzi
Dr. Robert S. Langer Sc.D.
Mr. John P. Mascotte
Mr. Raymond J. McGuire
Dr. Mary Lake Polan Ph.D.
Contact Information
Five Giralda Farms
Madison, NJ
973 660-5000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
